Final answer:
RhoGAM is administered to an Rh-negative client after the delivery of an Rh-positive newborn to prevent her from developing Rh sensitivity and protect future pregnancies from hemolytic disease of the newborn (HDN).
Step-by-step explanation:
RhoGAM is administered to an Rh-negative client after the delivery of an Rh-positive newborn to prevent her from developing Rh sensitivity. When an Rh-negative individual is exposed to Rh-positive blood (such as during childbirth), their immune system can produce anti-Rh antibodies. These antibodies can then cross the placenta in subsequent pregnancies and attack the Rh-positive fetus's red blood cells, leading to a condition called hemolytic disease of the newborn (HDN). RhoGAM contains antibodies that bind to the Rh antigen, preventing the Rh-negative mother from developing anti-Rh antibodies and protecting future pregnancies from HDN.